Keytruda (Pembrolizumab) Biosimilar
Various Cancers (PD‑1 inhibitor)
Process Scale‑upActive
Key Facts
About NeuClone
Australian biosimilar developer using a proprietary CHO platform to bring affordable biologics to market.
View full company profileTherapeutic Areas
Other Various Cancers (PD‑1 inhibitor) Drugs
| Drug | Company | Phase |
|---|---|---|
| Opdivo (Nivolumab) Biosimilar | NeuClone | Process Scale‑up |